Eiger BioPharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Gain from sale of priority review voucher
Income related to asset purchase agreement
Depreciation and amortization
Inventory write down
Net amortization of premiums and accretion of discounts on investments
Loss on extinguishment of debt
Non-cash interest expense
Reduction in the carrying amount of right-of-use assets
Common stock issued under Product Development Agreement
Stock-based compensation
Change in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Operating lease liabilities
Net cash used in operating activities
Investing activities
Purchase of debt securities available-for-sale
Proceeds from maturities of debt securities available-for-sale
Proceeds related to asset purchase agreement
Proceeds from sale of priority review voucher
Payments related to priority review voucher
Purchase of property and equipment
Net cash provided by investing activities
Financing activities
Issuance of common stock upon offering at-the-market, net of commissions
Public Offering
Total issuance of common stock upon offering at-the-market, net of commissions

Proceeds from issuance of common stock to lender
Proceeds from debt
Repayment of debt
Proceeds from issuance of common stock upon stock option exercises
Proceeds from issuance of common stock upon ESPP purchase
Payment of debt issuance costs
Proceeds from borrowings in connection with term loan, net of issuance costs
Repayment of accrued exit fee and second amendment fee
Repayment of term loan
Common stock offering costs
Net cash provided by financing activities

Effect of foreign exchange on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year
Supplemental disclosure of cash flow information:
Interest paid
Income taxes paid
Property and equipment purchases included in accounts payable and accrued liabilities
Common stock offering costs included in accounts payable and accrued liabilities
Right-of-use assets obtained in exchange for lease liabilities

Comments